Cargando…
Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy
Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458257/ https://www.ncbi.nlm.nih.gov/pubmed/37631232 http://dx.doi.org/10.3390/pharmaceutics15082017 |